UPDATE: The Cancer Drugs Fund
Posted: 1 March 2017 | | No comments yet
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer drugs that were not routinely available on the NHS.
In April 2016, NICE started to assess the cost and clinical effectiveness of every drug currently in the old CDF.
Speaking on the new process in March 2017, Sir Andrew Dillon, Chief Executive of NICE, said, “The system is working well. Companies are cooperating well with our reviews and the good news for patients is that more cancer drugs than ever are being recommended for routine use. As drugs move off the CDF, we free up funding for new drugs coming down the pipeline, so patients will have faster access to promising cancer drugs and the NHS makes the most of its resources.”
Modified appraisal process
The appraisal process for CDF drugs now allows NICE to make one of three recommendations:
- Recommend for routine commissioning – YES
- Not recommended for routine commissioning – NO
- Recommended for use within the CDF – NEW
DRUG | INDICATION | YES/ NO/ CDF |
Abiraterone | metastatic castration resistant prostate cancer |
|
Albumin Bound Paclitaxel | advanced adenocarcinoma of the pancreas |
|
Bendamustine | Chronic Lymphocytic Leukaemia OR low grade lymphoma OR mantle cell non-Hodgkin’s lymphoma OR relapsed multiple myeloma |
|
Bevacizumab | recurrent or metastatic cervical cancer OR advanced breast cancer OR advanced colorectal cancer OR low grade gliomas of childhood OR advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer |
|
Bortezomib | bortezomib naive relapsed multiple myeloma |
|
Bosutinib (Bosulif, Pfizer) | refractory chronic/ accelerated phase Chronic Myeloid Leukaemia | YES |
Brentuximab | refractory systemic anaplastic lymphoma OR relapsed or refractory CD30+ Hodgkin’s lymphoma |
|
Cabazitaxel | castrate-resistant Metastatic Prostate Cancer |
|
Cabozantinib (Cabometyx, Ipsen) | advanced renal cell carcinoma | NO Unreliable evidence |
Ceritinib (Zykadia, Novartis) | previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | YES |
Cetuximab (Erbitux, Merck) | head and neck cancer OR metastatic colorectal cancer | NO |
Clofarabine | acute lymphoblastic leukaemia OR acute myeloblastic leukaemia |
|
Crizotinib (Xalkori, Pfizer) | non-small cell lung cancer | YES |
Dasatinib | Ph+ acute lymphoblastic leukaemia OR chronic/ accelerated phase chronic myeloid leukaemia |
|
Enzalutamide | Metastatic Prostate Cancer |
|
Eribulin (Halaven, Eisai) | advanced breast cancer | YES |
Everolimus (Novartis) | advanced breast cancer AND renal cell carcinoma | YES |
Ibrutinib | Chronic Lymphocytic Leukaemia OR Mantle Cell Lymphoma |
|
Idelalisib | Chronic Lymphocytic Leukaemia |
|
Lenalidomide | myelodysplastic syndromes (MDS) OR multiple myeloma |
|
Nelarabine | T-cell acute lymphoblastic leukaemia OR refractory T-cell lymphoblastic non-Hodgkin’s lymphoma |
|
Nivolumab (Opdivo, Bristol-Myers Squibb) | squamous and non-squamous advanced non-small-cell lung cancer | Case was not clear cut then YES |
Ofatumumab | chronic lymphocytic leukaemi |
|
Osimertinib (Tagrisso, AstraZeneca) | lung cancer | YES |
Panitumumab | metastatic colorectal cancer |
|
Pegylated Liposomal Doxorubicin | Named sarcomas |
|
Pemetrexed (Alimta, Eli Lilly) | non-squamous non-small cell lung cancer | YES |
Peptide Receptor Radionucleotide Therapy (Octreotate) | neuroendocrine tumours |
|
Pertuzumab | locally advanced or metastatic breast cancer |
|
Pomalidomide | relapsed and refractory multiple myeloma |
|
Ponatinib (Iclusig, Incyte Corporation) | Chronic Myeloid Leukaemia with T315I Mutation OR Ph+ Acute Lymphoblastic Leukaemia with T315I Mutation | YES |
Radium-223 Dichloride | castration-resistant prostate cancer |
|
Regorafenib | gastro-intestinal stromal tumours (GIST) |
|
Ruxolitinib | symptomatic splenomegaly in primary myelofibrosis OR post polycythaemia vera myelofibrosis OR post essential thrombocythaemia myelofibrosis |
|
Sorafenib | hepatocellular carcinoma OR papillary or follicular thyroid cancer |
|
Sunitinib | pancreatic neuroendocrine carcinomas |
|
Temsirolimus | renal cell carcinoma |
|
Trastuzumab Emtansine | HER2-positive locally advanced/ unresectable OR metastatic (Stage IV) breast cancer |
|
Vandetinib | medullary thyroid cancer |
|
Vismodegib | locally advanced or metastatic Basal Cell Carcinoma |
|
